The psychoactive actions of the cannabinoids, and the distribution of the cannabinoid receptor in the central nervous system, suggest that cannabinoids mimic endogenous compounds(s) that modulate neural signals for mood, memory, movement and pain. Indeed, the recent identification and purification of an endogenous ligand, anandamide, for the cannabinoid receptor confirms this hypothesis. In addition, cannabinoids hold tantalizing promise as therapeutic agents for a range of illnesses. Anandamide (arachidonyl ethanolamide) may well be the first of a series of related compounds that serve as neuromodulators. Our understanding of how these compounds influence neuronal excitability is at an early stage, making further investigation important. This study will use patch clamp recording to identify ion channels modulated by cannabinoids and then will examine in detail the signal transduction pathway between them and the cannabinoid receptor. Emphasis will be placed both on direct guanine-nucleotide protein (G protein) modulation of ion channels as well as indirect actions as might follow from decreases in cAMP levels. In order to understand their role in normal cell physiology, the potency of cannabinoid agonists for different modulatory events will be determined. Site-directed mutagenesis will be used to define the regions of the cannabinoid receptor that mediate the interactions between the receptor and their associated G proteins(s). The results of these studies will increase our understanding of the signal transduction pathways of a novel and widespread neuromodulatory system. An understanding of these pathways is especially important in the therapeutic application of the cannabinoids, as it has been very difficult to separate the desired actions of cannabinoids (for example, analgesia) from their undesired side-effects (for example, dysphoria). Thus, knowledge of these pathways will allow a more rational assessment of the therapeutic potential of the cannabinoids, suggest new therapeutic targets for this class of drug and will offer insights into cellular consequences of their non-medicinal or recreational use.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29DA008934-05
Application #
2700879
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1994-06-01
Project End
1999-04-30
Budget Start
1998-05-15
Budget End
1999-04-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Washington
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Jin, W; Brown, S; Roche, J P et al. (1999) Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 19:3773-80
Netzeband, J G; Conroy, S M; Parsons, K L et al. (1999) Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture. J Neurosci 19:8765-77
Roche, J P; Bounds, S; Brown, S et al. (1999) A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol Pharmacol 56:611-8
Garcia, D E; Brown, S; Hille, B et al. (1998) Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J Neurosci 18:2834-41
Ummenhofer, W C; Brown, S M; Bernards, C M (1998) Acetylcholinesterase and butyrylcholinesterase are expressed in the spinal meninges of monkeys and pigs. Anesthesiology 88:1259-65
Garcia, D E; Li, B; Garcia-Ferreiro, R E et al. (1998) G-protein beta-subunit specificity in the fast membrane-delimited inhibition of Ca2+ channels. J Neurosci 18:9163-70
Twitchell, W; Brown, S; Mackie, K (1997) Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 78:43-50
Felder, C C; Joyce, K E; Briley, E M et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-50